Background/Aims: Cardiac hypertrophy is a major predisposing factor for heart failure and sudden cardiac death. Hyperoside (Hyp), a flavonoid isolated from Rhododendron ponticum L., is a primary component of Chinese traditional patent medicines. Numerous studies have shown that Hyp exerts marked anti-viral, anti-inflammatory, anti-oxidant, anti-cancer, anti-ischemic, and particularly cardio-protective effects. However, the effects of Hyp on cardiac hypertrophy have not been explored. The aims of this study were to determine whether Hyp could protect against cardiac remodeling and to clarify the potential molecular mechanisms. Methods: Neonatal rat cardiac myocytes were isolated and treated with different concentrations of Hyp, then cultured with angiotensin II for 48 h. Mice were subjected to either aortic banding or sham surgery (control group). One week after surgery, the mice were treated with Hyp (20 mg/kg/day) or vehicle by oral gavage for 7 weeks. Hypertrophy was evaluated by assessing morphological changes, echocardiographic parameters, histology, and biomarkers. Results: Hyp pretreatment suppressed angiotensin II-induced hypertrophy in cardiomyocytes. Hyp exerted no basal effects but attenuated cardiac hypertrophy and dysfunction, fibrosis, inflammation, and oxidative stress induced by pressure overload. Both in vivo and in vitro experiments demonstrated that the effect of Hyp on cardiac hypertrophy was mediated by blocking activation of the AKT signaling pathway. Conclusion: Hyp improves cardiac function and prevents the development of cardiac hypertrophy via AKT signaling. Our results suggest a protective effect of Hyp on pressure overload-induced cardiac remodeling. Taken together, Hyp may have a role in the pharmacological therapy of cardiac hypertrophy.
Introduction
Pathological cardiac hypertrophy is a major predisposing factor for heart failure and sudden cardiac death [1] . Generally, during hypertrophy, myocytes grow in size and contribute to protein synthesis [2] . Although this response may be initially beneficial, sustained cardiac hypertrophy ultimately leads to ventricular dilation and congestive heart failure [3] . Recently, many studies have illustrated that signaling pathways, such as mitogenactivated protein kinases (MAPKs), calcineurin-nuclear factor of activated T cells (NFAT), and phosphatidylinositol 3-kinase (PI3K)/AKT, play important roles in hypertrophic responses [4] . Therefore, pharmacological interventions targeting these signaling pathways may provide promising approaches for preventing cardiac hypertrophy. Unfortunately, despite the clinical use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and β-blockers, the death rate due to heart failure is increasing every year [2] . Thus, a better understanding of the intracellular signaling pathways that mediate cardiac hypertrophy and identification of novel drugs that disrupt the intracellular signaling pathways are greatly needed.
Hyperoside (Hyp; also known as quercetin 3-O-β-d-galactoside), a flavonoid isolated from Rhododendron ponticum L., is a primary component of Chinese traditional patent medicines. Recent studies have shown that Hyp possesses comprehensive pharmacological functions, including anti-inflammatory [5] , anti-cancer [6] , and anti-fibrosis effects [7] . Furthermore, increasing evidence suggests that Hyp protects against hypoxia/reoxygenationinduced injury in cardiomyocytes by suppressing Bnip3 expression [8] . Hou et al. reported that Hyp significantly improved cardiac function induced by ischemia/reperfusion injury by activating the Nrf2 signaling pathway [9] . It was also demonstrated that Hyp could induce apoptosis and inhibit growth via nuclear factor (NF)-κB signaling both in vitro and in vivo [10] . However, whether Hyp has a beneficial role in cardiac hypertrophy and, if so, the underlying mechanisms remain unclear. Therefore, we aimed to determine whether Hyp could attenuate cardiac hypertrophy and to identify the molecular mechanisms that may be responsible for any protective effects. It is known that pressure overload can activate the renin-angiotensin system and induce the release of angiotensin II (Ang II), which activates the Gα (q) protein-coupled receptor signaling pathway [11] . Thus, Ang II was used in vitro to induce remodeling in cardiomyocytes.
In this study, we investigated whether Hyp could ameliorate cardiac hypertrophy induced by pressure overload in mice. Our results showed that Hyp mitigated cardiac hypertrophy and fibrosis induced by pressure overload and preserved cardiac function. Our in vitro study revealed that pretreatment of Hyp could suppress Ang II-induced cardiomyocyte hypertrophy and oxidative stress. Mechanistically, we revealed that Hyp treatment prevented maladaptive remodeling, which was partially dependent on regulation of the AKT signaling pathway. Based on our results, we believe that Hyp would provide a potential therapeutic strategy for the treatment of cardiac hypertrophy and heart failure.
Echocardiography and hemodynamic evaluations
Echocardiography was performed on anesthetized (1.5% isoflurane) mice using a MyLab 30CV ultrasound system (Biosound Esaote, Inc., Indianapolis, IN) with a 10-MHz linear array ultrasound transducer. The LV was assessed at a frame rate of 120 Hz in both parasternal long-and short-axis views. The end-systolic and end-diastolic phases are defined as the stage of obtaining the minimum and maximum areas of the LV, respectively. LV end-systolic diameter (LVESD) and LV end-diastolic diameter (LVEDD) were measured at a mid-papillary muscle level at a sweep speed of 50 mm/s by LV M-mode tracing.
Cardiac catheterization was used to measure hemodynamic parameters in anesthetized (1.5% isoflurane) mice. A microtip catheter sensor (SPR-839; Millar Instruments, Houston, TX) was inserted into the right carotid artery and into the LV. After stabilizing for 15 min, the pressure signal and heart rate were continuously recorded with a Millar Pressure-Volume System (MPVS-400; Millar Instruments) with a Powerlab/4SP A/D converter and then stored and displayed on a personal computer. Data were processed using PVAN data analysis software.
Histological analysis and immunohistochemistry
Hearts were excised, immediately placed in 10% potassium chloride solution to ensure that they arrested during diastole, washed with saline solution, fixed with 10% formalin, and embedded in paraffin. Hearts were cut transversely to the apical side to visualize the LV and right ventricle. Heart sections (4 to 5 mm thick) were stained with hematoxylin and eosin (HE) for histopathology or picro-sirius red (PSR) for collagen deposition analysis. Cross-sectional areas of the myocytes were visualized with FITC-conjugated wheat germ agglutinin (WGA) (Invitrogen, Carlsbad, CA) staining. Single myocytes were measured using a quantitative digital image analysis system (Image Pro-Plus, version 6.0, Media Cybernetics, Rockville, MD). Between 100 and 200 LV myocytes were measured in each group. The LV collagen volume fraction was calculated from the sections stained for PSR, divided by the total area.
For immunohistochemistry, the heart sections were heated using the pressure cooker method for antigen retrieval, incubated with anti-CD31 (ab28364, Abcam, Cambridge, UK) or 4-hydroxynonenal (ab46545, Abcam) followed by incubation with goat anti-rabbit EnVisionTM+/horseradish peroxidase reagent, and stained using a DAB detection kit. For immunofluorescence, heart sections were incubated with anti-CD68 (ab125212, Abcam) and anti-CD45 antibody (ab10558, Abcam). The microvascular density per field was calculated using a quantitative digital image analysis system (Image Pro-Plus, version 6.0). Between 10 and 20 fields were calculated in each group.
Cell culture and treatment
Briefly, cardiac cells from neonatal rat hearts were isolated in phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.04% collagenase type II. Subsequently, neonatal rat cardiac myocytes (NRCMs) were purified by removing cardiac fibroblasts using a differential attachment technique (after 90 min, the cardiac fibroblasts was attached in the dishes, while the NRCMs were still suspended). NRCMs were then seeded at a density of 1 × 10 6 cells per well in six-well culture plates. After 48 h, the culture medium was replaced with serum-free DMEM/F12 for 12 h before stimulation with Ang II (1 μM 
Immunoflurescence staining
Immunofluorescence staining was performed with anti-α-actinin antibody (05-384, Millipore, Burlington, MA) to assess the cell cross-sectional area. After washing three times with PBS, the cells were fixed with RCL2 (RCL2-CS100, ALPHELYS, Plaisir, France) and permeabilized with 0.1% Triton X-100 (Amresco, Solon, OH) in PBS for 40 min, then stained with anti-α-actinin overnight at a dilution of 1:100 in 1% goat serum (GTX27481, GeneTex, Irvine, CA). The cells were then incubated with secondary goat antimouse antibody Irdye 800 CW (926-32210, LI-COR, Inc., Lincoln, NE) for 60 min. After washing with PBS, glass slides were used to mount cells on coverslips with ProLong Gold anti-fade reagent with 4'6-diamidino-2-phenylindole (DAPI; Invitrogen). The surface areas of NRCMs were measured using image analysis software (Image Pro-Plus, version 6.0) for 40 cells from each group.
Detection of reactive oxygen species in NRCMs
Myocytes were cultured in six-well plates and pretreated with Hyp and Ang II for the indicated times. Reactive oxygen species (ROS) were then detected by dichlorofluorescein diacetate assay (DCFH-DA). The cells were incubated with DCFH-DA (10 μM) for 60 min at 37°C, and immunofluorescence was detected using a fluorescence microplate reader (FL600, BioTek, Winooski, VT) normalized to the vehicle-PBS group to control for unwanted sources of variation (excitation/emission wavelength: 485/525 nm), by light microscopy (BX51TRF, Olympus Corporation, Tokyo, Japan).
Quantitative real-time PCR
Total RNA was isolated from heart tissues or NRCMs using TRIzol Reagent (Invitrogen), and RNA extracts (20 µg) were used to synthesize cDNA using Transcriptor First Strand cDNA Synthesis Kit (Roche, Mannheim, Germany). The mRNA levels of the indicated genes were quantified with real-time PCR using SYBR Green (Roche), and the results were normalized relative to GAPDH gene expression. The primers used for real-time PCR are shown in Table 1 .
Western blot analysis
Heart tissues or NRCMs were lysed in RIPA buffer (9806S, Cell Signaling Technology). Proteins were isolated as previously described [11, 12] , and the lysates (50 μg) were subjected to electrophoresis in 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes, followed by incubation with specific antibodies overnight at 4℃. Then, the membranes were incubated with a secondary antibody and scanned using the Odyssey Imaging System (LI-COR, Inc.). Specific protein expression levels were normalized relative to GAPDH protein for total cell lysates. The antibodies used for western blot are shown in Table 2 . 
Statistical analysis
All data were presented as the mean ± standard deviation. The differences between two groups were determined using unpaired Student's t test. Two-way analysis of variance with the post hoc Turkey test was used to compare the differences among groups. Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL). A value of P less than 0.05 was considered statistically different.
Results

Hyp inhibits cardiac hypertrophy in vitro
To determine the role of pretreatment with Hyp in Ang II-induced cardiac hypertrophy, we first evaluated the effect of Hyp on cardiomyocyte hypertrophy in vitro, using primary cultured NRCMs. Cardiac myocytes were pretreated with Hyp at the indicated concentrations for 24 h and subsequently stimulated with Ang II for 48 h, followed by Hyp with α-actinin to measure the cell size. Our results revealed that Hyp pretreatment markedly attenuated the increase in cardiac myocyte size seen in the presence of Ang II after 48 h of culture in a dose-dependent manner ( Fig. 1A-B ). In addition, Hyp pretreatment markedly reduced the increased mRNA and protein levels of the hypertrophic markers atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and β-myosin heavy chain (β-MHC) induced by Ang II, especially in the group treated with 10 μM Hyp ( Fig. 1C-D) . Thus, 10 μM Hyp was used in subsequent experiments. Then, the cardiomyocytes were co-incubated with Hyp (10 μM) and Ang II for different durations (6, 12, or 24 h ). The result demonstrated that Hyp inhibited Ang II-induced reactivation of ANP, BNP, and β-MHC expression in a time-dependent manner (Fig. 1E ). These findings suggested that Hyp protects against cardiac hypertrophy in vitro.
Hyp reduces cardiac hypertrophy and improves cardiac function after chronic pressure overload in mice
After exploring the effects of Hyp on cardiomyocyte hypertrophy in vitro, we sought to identify whether Hyp could antagonize the hypertrophic response induced by pressure overload. One week after AB surgery, mice were randomly assigned to the Hyp or vehicle treatment groups. Of note, in the sham groups, mice treated with Hyp did not show any pathophysiological alterations in cardiac structure or function compared with vehicle-treated mice. However, compared with the vehicle-treated mice that underwent AB, the myocardial hypertrophic response was significantly blocked by Hyp 8 weeks after surgery, as shown by a decrease in heart size and cardiomyocyte cross-sectional area (assessed by HE staining and FITC-conjugated WGA) in the Hyp-AB group ( Fig. 2A-B) . In parallel, the ratios of HW/ BW, HW/TL, and LW/BW were significantly decreased in Hyp-treated mice compared with vehicle-treated mice 8 weeks after AB (Fig. 2C) . Moreover, the mRNA expression levels of the hypertrophic markers ANP, BNP, and β-MHC were inhibited in the Hyp-treated mice compared to vehicle-treated animals (Fig. 2D) . In echocardiography and hemodynamic evaluations, we found that systolic and diastolic functions were improved after treatment with Hyp (with decreased LVEDD and LVESD, and increased fractional shortening and ejection fraction, Table 3 ). LV pressure-volume loops also showed preserved systolic function in Hyp-treated mice compared with the vehicle-treated mice in the AB groups (with increased dp/dt max , and dp/dt min , Table 3 ). These results suggest that Hyp could improve cardiac function and suppress cardiac hypertrophy after AB surgery.
Hyp attenuates cardiac fibrosis and inflammation in vivo
To further investigate the mechanism by which Hyp inhibits cardiac hypertrophy, we examined the ability of Hyp to inhibit fibrosis. Our results showed that interstitial and perivascular fibrosis were dramatically increased in the vehicle-treated hearts subjected to chronic AB, which was limited in Hyp-treated hearts (Fig. 3A-B) . Moreover, the mRNA expression levels of fibrotic markers (eg, collagen I, collagen III, and connective tissue growth factor) also demonstrated a blunted fibrotic response in Hyp-treated mice, compared with (Fig. 3C) . To examine the molecular mechanisms underlying the role of Hyp in collagen synthesis, we assessed the effect of Hyp on Smad cascade activation. The increased levels of transforming growth factor (TGF)-β1, Smad2, and Smad3 phosphorylation were attenuated in Hyp-treated mice after AB surgery ( Fig. 3D-E) . These results indicated that treatment with Hyp could alleviate the fibrotic response induced by chronic pressure overload.
Hyp inhibits inflammatory responses following chronic pressure overload
Inflammation plays an important role in the pathology of cardiovascular diseases [14, 15] . As demonstrated by immunehisto-chemical staining, the number of inflammatory cells (leukocytes and macrophages) infiltrating into the myocardium of Hyp-treated mice was significantly decreased after AB, compared with vehicle-treated mice (Fig. 4A-C) . Moreover, our results showed that, compared with vehicle-treated mice, the mRNA levels of inflammatory factors, including interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α), and monocyte chemoattractant protein-1 (MCP-1) were decreased in Hyp-treated mice after AB (Fig. 4D) . Decreased microvascular density was previously shown to be involved in hypertrophic responses. In the present study, we found that Hyp treatment increased microvascular density in hypertrophic hearts as assessed by CD31 staining (Fig. 4E ). These results demonstrate that Hyp inhibits inflammation in response to chronic pressure overload.
Hyp inhibits oxidative stress in vitro and in vivo
Previous studies have found that Hyp plays an essential role in regulating oxidative stress [16, 17] . Therefore, we next explored the effect of Hyp on cellular ROS generation. Hyp pretreatment inhibited Ang II-induced ROS generation as assessed by DCFH-DA assay using an enzyme-linked immunosorbent assay reader and light microscopy ( Fig. 5A-B) . Hyp pretreatment also increased the mRNA levels of superoxide dismutase (SOD) and glutathione peroxidase (Gpx) and decreased the mRNA levels of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) P67 phox in cardiomyocytes (Fig. 5C ). We also observed increased activity of Gpx and SOD in Hyp-treated mouse hearts ( Fig. 5D-E) . Consistently, decreased levels of the lipid peroxidation product 4-hydroxynonenal were observed in Hyptreated mice compared with vehicle-treated animals (Fig. 5F ). Hyp treatment increased the protein levels of SOD and Gpx and decreased the protein levels of P67 phox in mouse hearts ( Fig. 5G-H) . Altogether, the above results suggested that Hyp pretreatment could inhibit oxidative stress both in vitro and in vivo.
Hyp inhibits the AKT signaling pathway in response to hypertrophic stimuli
The above results suggested that Hyp protects against pressure overload-induced cardiac remodeling. However, the molecular mechanism by which Hyp regulates the hypertrophic response remains unknown. Given that the AKT signaling pathway has been demonstrated to play an important part in the development of cardiac hypertrophy, we first examined whether Hyp affected AB-induced activation of the AKT signaling pathway. We exposed NRCMs to 1 μM Ang II for 48 h with or without pretreatment with 10 μM Hyp. Of interest, we observed that Ang II induced significant activation of the AKT pathway. However, Hyp pretreatment markedly suppressed the activation of AKT, GSK3β, mTOR, and eIF4e ( Fig.  6A-B) . In line with the in vitro findings, AB induced a significant increase in phosphorylated Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry levels of AKT, GSK3β, mTOR, and eIF4e. Nevertheless, activation of AKT, GSK3β, mTOR, and eIF4e was blocked in Hyp-treated mouse hearts (Fig. 6C-D) . Taken together, these results demonstrated that Hyp may suppress cardiac hypertrophy through inhibition of AKT signaling in vitro and in vivo.
Protective effect of Hyp against cardiac hypertrophy was largely dependent on regulation of the AKT signaling pathway
In order to confirm that Hyp inhibited cardiomyoctye hypertrophy via inhibition of the AKT signaling pathway, we performed additional in vitro experiments. NRCMs were treated with MK-2206, a novel orally active allosteric AKT inhibitor [18] , for 1 h and then with Ang II for 48 h after treatment with Hyp for 24 h. As expected, MK-2206 significantly attenuated Ang II-induced cell enlargement and the expression levels of hypertrophic biomarkers. However, Cellular Physiology and Biochemistry
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Hyp did not affect the decreased hypertrophic response in MK-2206-treated cells (Fig.  7A-C) . Moreover, we found that MK-2206 significantly inhibited Ang II-induced oxidative stress, whereas Hyp did not affect the decreased oxidative stress in MK-2206-treated cells (Fig. 7D-F) . Collectively, these findings confirm the protective effect of Hyp against cardiac hypertrophy through blockade of activation of the AKT signaling pathway.
Discussion
Although hypertrophy is initially a compensatory mechanism, sustained cardiac hypertrophy ultimately leads to decompensated heart failure [3] . Much research has been conducted to investigate the progression of cardiac hypertrophy to heart failure, but the mechanism by which this process is suppressed remains unclear. Therefore, it is crucial to clarify the molecular mechanism underlying cardiac hypertrophy and the function of antihypertrophic targets. In recent decades, various signaling pathways that mediate the process of hypertrophic development have been identified, such as MAPKs, calcineurin/NFAT, and PI3K/AKT pathways. Blocking these signaling pathways effectively may provide a promising method for inhibiting cardiac hypertrophy and heart failure. The present challenge is to identify pharmacological agents that selectively modulate specific signaling pathways and thereby prevent pathological cardiac hypertrophy. To date, no effective drugs have been found to treat cardiac hypertrophy-related molecular changes. In this study, our in vitro study revealed that Hyp could prevent Ang II-induced cardiomyocyte hypertrophy. Moreover, by using a mechanical overload induced cardiac remodeling model, our data showed that Hyp can inhibit cardiac hypertrophy, fibrosis, inflammation, and oxidative stress in response to stress in vivo. In addition, we demonstrated that Hyp ameliorated cardiac hypertrophy partially by modulating the AKT signaling pathway. To our knowledge, our study is the first to demonstrate that Hyp can alleviate adverse cardiac remodeling and regulate hypertrophic signaling due to chronic pressure overload. Studies have explored the anti-viral, anti-inflammatory, anti-oxidant, and anti-cancer activities of Hyp [19, 20] . In addition, Hyp was reported to exert beneficial cardiovascular effects, such as anti-ischemic [21] and anti-depressant [22] activities, and cytoprotective properties against oxidative stress [23] . It was previously reported that Hyp significantly improved LV end-diastolic pressure and LV developed pressure induced by ischemia/ reperfusion injury via activation of Nrf2 signaling [9] . In addition, Li et al. demonstrated that Hyp could induce apoptosis and inhibit growth via the NF-κB signaling pathway both in vitro and in vivo [10] . However, the potential role of Hyp and its mechanism of action in cardiac hypertrophy remain unknown. Here, we revealed that Hyp is an anti-hypertrophic factor that attenuates cardiac hypertrophy by blocking activation of the AKT signaling pathway.
Cardiac fibrosis is a major feature of hypertrophic cardiomyopathy and contributes to ventricular dysfunction and life-threatening arrhythmia [13, 24] . Our in vivo study showed that Hyp treatment reduced the pressure overload-induced fibrotic response. We examined the role of TGF-β/Smad signaling in the progression of fibrosis. We found that expression levels of TGF-β1, p-Smad2, and p-Smad3 induced by pressure overload were attenuated in Hyp-treated mice, which is consistent with previous findings [25] . Our data showed that Hyp reduced TGF-β/Smad signaling in hypertrophied hearts and inhibited collagen synthesis.
Mounting evidence has strongly suggested that inflammation plays a critical role in the development of cardiac hypertrophy and heart failure [14, 15] . In this study, we discovered that Hyp treatment was able to repress inflammatory cell infiltration into the myocardium of AB mice. Moreover, levels of inflammatory cytokines, such as IL-1a, IL-6, TNF-α, and MCP-1, which promote progression of cardiac hypertrophy and heart failure, increased in the hypertrophic hearts [26] but were normalized by Hyp treatment. We speculate that the protective effects of Hyp on cardiac dysfunction after AB surgery may be partially associated with the suppression of cardiac inflammation.
Evidences suggest that oxidative stress is a crucial factor in the development and progression of cardiac hypertrophy, as it is involved in various molecular mechanisms that contribute to cellular dysfunction, protein and lipid peroxidation, and DNA damage and can lead to irreversible cell damage and death [27, 28] . In parallel, oxidative stress has a role in the regulation of cell signaling in cardiomyocytes under afterload stress conditions, favoring maladaptive cardiac remodeling [29, 30] . During our investigations into the mechanism responsible for Hyp-mediated protection against pathological cardiac remodeling, we demonstrated a dramatic suppression of oxidative stress by Hyp following hypertrophic stress.
The role of the AKT signaling pathway in cardiac hypertrophy has been well established [31] . Targeted overexpression of constitutively active AKT in the heart increased organ size, while expression of a dominant-negative mutant resulted in the opposite outcome [32] . The hypertrophic response following AKT activation was apparently associated with the AKT downstream targets GSK3β and mTOR [33] . Increasing evidence suggests that GSK3β functions as a negative regulator of cardiac hypertrophy that blocks cardiomyocyte hypertrophy in response to endothelin 1, Ang II, phenylephrine, or isoproterenol [34] . AKT signaling pathway target mTOR appears critical for cardiac hypertrophy during chronic pressure overload or neurohumoral factors [33] . Activation of mTOR and its downstream target eIF4e mediates cardiomyocyte protein synthesis, which is associated with cardiac angiogenesis, fibrosis, and hypertrophy [35] . An important finding of the present study is that the increases in AKT, GSK3β, mTOR, and eIF4e phosphorylation levels in response to hypertrophic stress were largely blocked by Hyp. Our additional in vivo experiments confirmed that Hyp attenuates cardiac hypertrophy by blocking activation of the AKT signaling pathway. Therefore, Hyp could attenuate cardiac hypertrophy in response to hypertrophic stress via inhibition of AKT signaling.
Conclusion
In this study, Hyp was administrated 1 week after AB surgery, which suggests that Hyp could be a potential novel treatment for established cardiac remodeling. Yet, in vitro, Hyp was administered 24 h before Ang II stimulation, which implies that Hyp may be a potential new strategy to prevent cardiac remodeling before it is established. In summary, the present findings provide the first evidence that Hyp protects against cardiac hypertrophy in response 
